Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction
oleh: Giovanni Maria Fusco, Luigi Cirillo, Francesco Mastrangelo, Francesco Romano, Ernesto Di Mauro, Gianluigi Cacace, Gianluca Spena, Annamaria Iannicelli, Corrado Aniello Franzese, Vincenzo Mirone, Roberto La Rocca, Luigi Napolitano
| Format: | Article |
|---|---|
| Diterbitkan: | PAGEPress Publications 2023-05-01 |
Deskripsi
To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples’ relationship, and quality of life. [...]